| 研究成果： |
课题组研究着重于疫苗制剂的设计开发，质量控制和效果评估。根据不同疫苗设计需求，建立多模式佐剂/抗原递送平台，并探索各种佐剂/抗原组合在不同免疫策略下的免疫响应和相关机制。此外，课题组热衷于蛋白多肽生物大分子的酶解稳定性及其在体外和离体膜屏障模型中的递送研究，策略包括：肽结构修饰、聚合物纳米粒/微粒、生物材料的功能化修饰和自主装系统。
Selected Publications： 1. Zheng Y, Bian L, Zhao H, Liu Y, Lu J, Liu D, Zhang K, Song Y, Luo Y, Jiang C*, Chen Y, Zhang Y*, Kong W. Respiratory Syncytial Virus F subunit vaccine with AS02 adjuvant elicits balanced, robust humoral and cellular immunity in BALB/c mice. Front Immunol. (2020), 11:526965
2. Li F, Chen Y, Liu S, Pan X, Liu Y, Zhao H, Yin X, Yu C, Kong W, Zhang Y*. The effect of size, dose, and administration route on zein nanoparticle immunogenicity in BALB/c mice. Int J Nanomedicine. (2019), 14:9917-9928 3. Chen XR; Li B; Yu JF; Zhang Y; Gu TJ; Zhang Y*; Kong W; Wu YG*. Comparison of four adjuvants revealed for strongest protection against lethal pneumococcal challenge following immunization with PsaA-PspA fusion protein and AS02 as adjuvant. Med Microbiol Immun. (2019), 208(2):215-226. 4. Shi W, Kou YM, Xiao JH, Zhang LJ, Gao F, Kong W, Su WH, Jiang CL*, Zhang Y*. Comparison of immunogenicity, efficacy and transcriptome changes of inactivated rabies virus vaccine with different adjuvants. Vaccine. (2018), 36(33):5020-5029.
5. Li F, Chen Y, Liu SB, Qi J, Wang WY, Wang CH, Zhong RY, Chen ZJ, Li XM, Guan YZ, Kong W, Zhang Y*. Size-controlled fabrication of zein nano/microparticles by modified anti-solvent precipitation with/without sodium caseinate. Int. J. Nanomedicine. 2017,12: 8197—8209.
6. Feng J, Chen Y, Li F, Cui LL, Shi NQ, Kong W, Zhang Y*. Synthesis, Characterization and in vitro evaluation of a novel glycol chitosan-EDTA conjugate to inhibit aminopeptidase-mediated degradation of thymopoietin oligopeptides. Molecules. 2017, 22(8): 1253.
7. Zhang Y*, Cui LL, Li F, Shi NQ, Li CL, Yu XH, Chen Y*, Kong W. Design, fabrication and biomedical applications of zein-based nano/micro-carrier systems. Int J Pharm. 2016,513(1-2):191-210.
8. Zhang Y*, Feng J, Cui LL, Zhang YB, Li WZ, Li CL, Shi NQ, Chen Y*, Kong W. Investigation into efficiency of a novel glycol chitosan-bestatin conjugate to protect thymopoietin oligopeptides from enzymatic degradation. J Pharm. Sci. (Ronald T. Borchardt Dedicated Issue) 2016,105(2): 828-837.
9. Sun YN, Wang MS, Sun BX, Li F, Liu SB, Zhang Y*, Zhou Y, Chen Y*, Kong W. An investigation into the gastrointestinal stability of exenatide in the presence of pure enzymes, everted intestinal rings and intestinal homogenates. Biol Pharm Bull. 2016,39(1):42-48.
10. Zhang Y*, Cui LL, Chen Y, Zhang H, Zhong J, Sun YN, Shi NQ, Li CL, Kong W*. Zein-based nanofibres for drug delivery: Classes and current applications. Curr Pharm Des. 2015,21(22)：3199-3207.
11. Zhang Y*, Cui LL, Che XX, Zhang H, Shi NQ, Li CL, Chen Y*, Kong W. Zein-based films and their usage for controlled delivery: Origin, classes and current landscape. J Control Release. 2015,206:206-217.
12. Shi NQ*, Qi XR*, Xiang B, Zhang Y. A survey on “Trojan Horse” peptides: Opportunities, issues and controlled entry to "Troy". J Control Release. 2014,194:53-70.
13. Wang MS, Zhang Y, Sun BX, Sun YN, Gong X, Wu YG, Zhang XZ, Kong W*, Chen Y*. Permeability of Exendin-4-Loaded Chitosan Nanoparticles across MDCK Cell Monolayers and Rat Small Intestine. Biol Pharm Bull. 2014,37(5):740-747.
14. Wang MS, Zhang Y, Feng J, Gu TJ, Dong QG, Yang X, Sun YN, Wu YG, Chen Y*, Kong W*. Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly (d,l-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4. Int. J. Nanomedicine. 2013,8:1141-54.
15. Dong QG, Zhang Y, Wang MS, Feng J, Zhang HH, Wu YG, Gu TJ, Yu XH, Jiang CL, Chen Y*, Li W, Kong W*. Improvement of enzymatic stability and intestinal permeability of deuterohemin-peptide conjugates by specific multi-site N-methylation. Amino Acids. 2012,43(6):2431-41.
16. Wang MS, Sun BX, Feng J, Zhang HH, Liu B, Li C, Chen Y*, Zhang Y*, Kong W. Investigation of transport mechanism of exendin-4 across MDCK cell monolayers. Biol. Pharm. Bull. 2012,35(5):745-52.
17. Zhang Y*, Deng YJ, Wang XL, Xu JH, Li ZQ*. Conformational and bioactivity analysis of insulin: freeze-drying TBA/water co-solvent system in the presence of surfactant and sugar. Int. J. Pharm. 2009,371(1-2):71-81.
18. Zhang Y, Deng YJ*, Lu M, Duncan Q.M. Craig, Li ZQ*. A spectroscopic investigation into interaction between bile salts and insulin in alkaline aqueous solution. J. Colloid Interface Sci. 2009,337(2):322-331.
19. Hao AJ, Deng YJ*, Li TF, Suo XB, Cao YH, Hao YL, Zhang Y. Degradation kinetics of fluorouracil-acetic-acid-dextran conjugate in aqueous solution. Drug Dev. Ind. Pharm. 2006,32(6):757-63.
20. Hao YL, Deng YJ*, Chen Y, Wang KZ, Hao AJ, Zhang Y. In-vitro cytotoxicity, in-vivo biodistribution and antitumor effect of PEGylated liposomal topotecan. J. Pharm. Pharmacol. 2005,57: 1279-1287.
专著 1. Zhang Yong*, Cui Lili, Chen Yan and Kong Wei. Chapter 1: Exendin-4 and Its Derivatives for Diabetes and Obesity: Old Story and New Hope. (Invited Chapter), in Ed, Atta-ur-Rahman, Frontiers in Clinical Drug Research- Diabetes and Obesity, Bentham Science Publishers, 2016, volume 3, page: 3-58. DOI: 10.2174/9781681082479116030003; ISBN: 978-1-68108-248-6. 2. 张勇，陈妍. 第十七章 脂质体在其他给药系统中的应用.《脂质体技术》（主编：邓英杰，书号：ISBN:978-7-117-08409-3/R.8410），人民卫生出版社，2007。
专利
1. 张勇，陈妍，孔维。苯丁抑制素乙二醇壳聚糖及其制备方法（专利号201410260315.x）
学术会议 1.新型佐剂在呼吸道病毒性疫苗中的临床应用。中国生物制品年会，2020.11，珠海
2.上市疫苗佐剂类型及作用机理。中国疫苗创新论坛，2020.09，泰州 3.Adjuvants for Vaccine Development. AIDS and Vaccines, 2018.09, Changchun
|
